Tiprostanide is a 13-thia-PGE1 analog which also contains a p-benzamidophenyl ester, presumably to enhance crystallinity and stability. Although originally targeted and evaluated as an antihypertensive agent, emphasis was switched to an antiulcer indication because of disappointing clinical results. Tiprostanide has two distinct properties in the human stomach, viz. antisecretory and protective, which are independent of each other. Antisecretory prostaglandins protect the human stomach against aspirin and bile salts in doses which are much smaller than the threshold antisecretory ones.

Mexiprostil (also known as MDL 646), a synthetic prostaglandin was developed as a potent antiulcer agent. Experiments on animals have revealed that this drug possessed gastric protection, diarrheogenic and arterial hypotensive effects. The supposed local activity coupled with the antisecretory effects and the good tolerability made it interesting to test mexiprostil as an anti-ulcer agent in man. However, information about the further development of the drug is not available.

Froxiprost (ONO-995), a synthetic analog of dinoprost, is a prostanoid receptor agonist. Froxiprost is active in contracting the uterine smooth muscle and is used as a pharmacological tool.

Hoe 260 is a long-lasting and potent antisecretory and cytoprotective prostaglandin E2-analogue, having a favourable split between therapeutic gastric effects, effect on blood pressure and intestinal side effects. It is a prostanoid receptor agonist with antiulcerogenic activity.

Eganoprost is a prostaglandin derivative.

Etiproston is a synthetic analog of prostaglandin F2α. Etiproston induces luteal regression. Etiproston is used in veterinary.

Evatanepag (CP-533,536) is a prostaglandin E2 EP2 receptor agonist. It stimulates new bone formation on trabecular, endocortical, and periosteal surfaces and enhances fracture healing. Evatanepag was under development with Pfizer as a bone formation stimulant for therapeutic use in the healing of fractures.

Posaraprost is the anti-inflammatory compound.

Butaprost, a structural analog of PGE2, is a selective agonist for the EP2 receptor subtype. EP2 receptors are expressed on human neutrophils and on respiratory, vascular, and uterine smooth muscle. Butaprost binds with about 1/10 the affinity of PGE2 to the recombinant murine EP2 receptor and does not bind appreciably to the other murine EP receptors or the DP, TP, FP, and IP receptors. Butaprost has frequently been used to pharmacologically define the EP receptor expression profile of various human and animal tissues and cells. Butaprost effectively reduces the subconjunctival scarring response. Given the significance of wound healing modulation in blebs, butaprost's inhibitory effect on subconjunctival Tenon's fibroblasts may be beneficial in managing postoperative scarring in glaucoma surgery.

Doxaprost is an orally active bronchodilator. Doxaprost was 73 and 32 times more potent that (+/-) 11-deoxy PGE1 by the aerosol and i.v. routes, respectively. Doxaprost also demonstrated a longer duration of effect. Doxaprost is indicated for the treatment of symptoms of benign prostatic hyperplasia and hypertension. Common side effects are: dizziness, weakness and rarely fainting, especially at the beginning of the medication use. Doxaprost potentiates the action of lowering the blood pressure of other alpha-blockers and anti-hypertensives.